All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage M0/M1A/M1B stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - L2 - all population, Ipilimumab (10 mg/kg) vs. ipilimumab alone, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.84 [0.71; 1.00]
0.84 [0.71 ; 1.00 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable progression or deaths (PFS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.89 [0.66; 1.21]
0.89 [0.66 ; 1.21 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable DCRdetailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.19 [0.86; 1.63]
1.19 [0.86 ; 1.63 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable objective responses (ORR)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.31 [0.86; 2.00]
1.31 [0.86 ; 2.00 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 727 NA not evaluable TRAE (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.40 [1.76; 3.28]
2.40 [1.76 ; 3.28 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.70 [1.86; 3.92]
2.70 [1.86 ; 3.92 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable TRAE leading to death (grade 5)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.00 [0.36; 10.99]
2.00 [0.36 ; 10.99 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable TRAE leading to discontinuation (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.97 [1.40; 2.78]
1.97 [1.40 ; 2.78 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.27 [1.53; 3.38]
2.27 [1.53 ; 3.38 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Colitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.16 [0.96; 4.84]
2.16 [0.96 ; 4.84 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.84 [1.05; 3.21]
1.84 [1.05 ; 3.21 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.30 [0.99; 5.36]
2.30 [0.99 ; 5.36 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.82 [1.14; 2.91]
1.82 [1.14 ; 2.91 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
2.51 [0.48 ; 13.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.01 [0.30; 120.38]
6.01 [0.30 ; 120.38 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.43 [0.54; 3.81]
1.43 [0.54 ; 3.81 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Increase AST TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.11 [1.01; 65.20]
8.11 [1.01 ; 65.20 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.14 [1.36; 27.62]
6.14 [1.36 ; 27.62 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Nervous system disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
8.03 [0.42 ; 152.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pericarditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
8.03 [0.42 ; 152.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Polymyalgia Rheumatica TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritus TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.99 [0.14; 7.10]
0.99 [0.14 ; 7.10 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
2.51 [0.48 ; 13.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
8.03 [0.42 ; 152.51 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.40 [0.44; 4.45]
1.40 [0.44 ; 4.45 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Uveitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-04 15:37 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 69
- treatments: 558